Abstract
Alectinib can cause rare, but severe hypersensitivity. The cross-reactivity between different ALK inhibitors is unknown and desensitization is the only reported management. We hereby report the first case of severe delayed hypersensitivity developed in a lung cancer patient treated by alectinib, who was successfully managed by switching to brigatinib, another ALK inhibitor. The patient achieved excellent anti-tumor response to brigatinib. Our case provides an alternative and safe strategy in patients with alectinib-related hypersensitivity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 73-77 |
| Number of pages | 5 |
| Journal | Lung Cancer: Targets and Therapy |
| Volume | 9 |
| DOIs | |
| State | Published - 2018 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Alectinib
- Brigatinib
ASJC Scopus subject areas
- Oncology
Fingerprint
Dive into the research topics of 'Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: A case of successful switch to an alternative ALK inhibitor and systematic review of the literature'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS